Lung Cancer

Datopotamab deruxtecan was effective in patients with TROP2-QCS biomarker-positive tumors for non–small cell lung cancer

Lazertinib with amivantamab was found to be similar in efficacy to osimertinib in the MARIPOSA study.

Previously, the FDA granted fast track designation to ABD-147 (Abdera Therapeutics Inc) for extensive stage small cell lung cancer.

With diagnostic tools, oncology pharmacists and other health care providers can help to identify treatments that have the best probability of working for a specific patient.

Pharmacists have been shown to contribute to improved adherence rates, therapy optimization, patient safety, and cost-savings.

The financial burden has increased significantly since 2015.

The breakthrough therapy designation was granted based on ongoing data from the ARTEMIS-001 phase 1 open-label, multi-center trial.

The combination is the first and only multi-targeted chemotherapy-free regimen that demonstrated superiority compared with osimertinib for non–small cell lung cancer (NSCLC).

Durvalumab is a human monoclonal antibody that targets and binds to PD-L1 to interrupt tumor immune-evasion tactics.

The supplemental biologics license application was granted based on results from the ADRIATIC phase 3 trial among individuals with limited stage small cell lung cancer.

The decision is based positive data from the Deltacel-01 clinical trial.

Pharmacists play a vital role in therapy selection.

The trial evaluated a fixed-dose combination of vibostolimab and pembrolizumab in combination with chemotherapy as a first-line treatment for extensive-stage small cell lung cancer.

Pharmacists will play an integral role in this evolving field, from patient education and monitoring AEs to new therapeutic developments and treatment protocols.

The study is expected to include 460 individuals that will be randomly treated with 12mg of ifinatamab deruxtecan or chemotherapy chosen by the health care provider.

Alan Chin, PharmD, BCOP, examines the PALOMA-3 trial's influence on the treatment of EGFR-mutated metastatic NSCLC and explores the evolving role of antibody-drug conjugates (ADCs) in the therapeutic landscape of EGFR-mutated NSCLC.

Helping patients overcome barriers to accessing these treatments is a vital role for pharmacists, who can support patients who are looking to quit.

A pharmacy expert explores infusion-related reactions associated with amivantamab, providing guidance on managing and preventing these reactions, while also addressing the role of split-dosing, premedications, and steroids in the treatment paradigm.

Alan Chin, PharmD, BCOP, presents an overview of the most prevalent and common adverse reactions associated with EGFR-targeted therapies in metastatic NSCLC and shares strategies to mitigate toxicities, with a focus on managing dermatologic events such as rash and itching.

Small cell lung cancer is initially responsive to platinum-based chemotherapy, but it does develop drug resistance over time, furthering the need for better treatment options.

A clinical pharmacy specialist examines treatment strategies for EGFR exon 20 insertion mutations, referencing data from the PAPILLON trial, and addresses the challenges associated with managing brain metastases in this patient population.

Cara Chang, PharmD, BCOP, provides a comprehensive analysis of the MARIPOSA-2 trial, evaluating the various study arms and interpreting the practice-changing data presented.

A biologics license application (BLA) for patritumab deruxtecan receives complete response letter due to inspection findings at third-party manufacturer.

Jordyn P. Higgins, PharmD, BCOP, discusses the evolving treatment landscape for small cell lung cancer (SCLC).

A renowned lung cancer pharmacy specialist presents the efficacy and safety data from the phase 3 FLAURA2 trial, emphasizing progression-free survival and overall survival outcomes, and shares additional insights from the MIRAPOSA study.

Cara Chang, PharmD, BCOP, examines the prevalence of EGFR positivity, provides an overview of clinically relevant EGFR mutations, and discusses therapeutic options for EGFR-positive mutations.

Repotrectinib has also shown significant efficacy in ROS1 fusion-positive non¬–small cell lung cancer (NSCLC), which was also studied in the TRIDENT-1 trial.

Osimertinib demonstrates improved progression-free survival for stage 3 epidermal growth factor receptor-mutated (EGFRm) lung cancer.

Nicolas Girard, MD, PhD, discusses the results of the PALOMA-2 trial, highlighting the subcutaneous (SC) delivery of amivantamab combined with lazertinib as a first-line treatment for advanced non-small cell lung cancer (NSCLC) with EGFR mutations.

The PALOMA-3 trial showed subcutaneous amivantamab was better than IV for lung cancer patients.